Royalty Pharma RPRX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's operating income?
- Royalty Pharma (RPRX) reported operating income of $563.04M in Q1 2026.
- How has Royalty Pharma's operating income changed year-over-year?
- Royalty Pharma's operating income increased by 5.4% year-over-year, from $534.18M to $563.04M.
- What is the long-term trend for Royalty Pharma's operating income?
- Over 3 years (2021 to 2025), Royalty Pharma's operating income has grown at a 2.9% compound annual growth rate (CAGR), from $1.43B to $1.56B.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.